MGI/SuperGen Estimate Dacogen Peak Sales Of $250 Mil.; Action Date Is Sept. 1
This article was originally published in Pharmaceutical Approvals Monthly
MGI and SuperGen estimate their myelodysplastic syndrome agent Dacogen has a market potential of $250 mil., SuperGen said July 21.
You may also be interested in...
MGI Pharma’s recently submitted oral mucositis therapy Saforis and newly approved myelodysplastic syndromes agent Dacogen top a "deep and maturing pipeline" projected to drive corporate sales to $1 bil. by 2010, according the company.
MGI/SuperGen’s myelodysplastic syndromes therapy Dacogen (decitabine) is "approvable" at FDA pending submission of additional analysis of transfusion data
MGI Pharma's acquisition of Guilford will forge a two-product acute care sales force